Companies
|
- Public (NASDAQ: AVAN) biopharmaceutical company that uses novel applications of immunology to prevent and treat diseases headquartered in Needham, Massachusetts
- Monetized a Royalty for up to $61 million based on Rotarix, a vaccine for the prevention of rotavirus, marketed by GlaxoSmithKline
- Closed in May 2005
- World's third largest pharmaceutical company (EURONEXT: SAN; NYSE: SNY), ranking number one in Europe and headquartered in Paris, France
- Aventis monetized a Royalty for up to $115 based on Lunesta™, for insomnia, marketed by Sepracor. This was completed just prior to Sanofi's acquisition of Aventis to satisfy Federal Trade Commission requirements.
- Closed in October 2004
- Public (NASDAQ: DYAX) drug discovery company focused on developing novel biotherapeutic products with an emphasis on cancer and inflammatory indications. Dyax utilizes its proprietary phage display technology to identify antibody, small protein and peptide compounds for clinical development and leverages this technology through its Licensing and Funded Research Program. The company is headquartered in Cambridge, Massachusetts
- Invested up to $35 million in future royalties, milestones and fees from Dyax’s Licensing and Funded Research Program
- Closed in August 2006
- Public company (LSE: IOV) specializing in the development of pulmonary products for the treatment of respiratory disorders and other serious diseases, based in Nottingham, UK
- Through two separate financings, invested an aggregate of £22.5 million in a Royalty in ExtranealTM, a peritoneal dialysis solution for renal patients, and a Revenue Interest based on Adept®, a solution for the prevention of postoperative adhesions, both of which are marketed by Baxter
- Closed in June 2001 and February 2002
- Vernalis PLC (LSE: VER) is a publicly traded biopharmaceutical company based in the UK focused on the development of products for the treatment of central nervous system disorders
- Monetized 90% of future payments due to the company under its exclusive license and supply agreement for the commercialization of frovatriptan in Europe and certain other territories
- The company received €18.4 million in cash upfront from Paul Capital Healthcare
- Closed in April 2008
|
|
Academic Institutions & Universities
|
- Founded over one hundred years ago, Aston is known for world class teaching quality and research and a graduate employment record that is consistently the best in the UK, with strong links with industry, government and commerce. The university is located in Birmingham, England
- Aston monetized a portion of its royalty in Temodar® for $7.4 million upfront and retains the right to receive royalties above certain sales thresholds. Temodar is used for the treatment of newly diagnosed brain tumors and is marketed by Schering-Plough
- Closed in July 2002
- Leading oncology focused technology transfer and development company that aims to maximize cancer patient benefit from publicly funded research based in London, England
- Monetized a Royalty for $20 million
- Closed in April 2003
- Institution that ranks third nationally among all pediatric centers in research grants from the National Institutes of Health
- Monetized a royalty for $24 million, in Rotarix®, a vaccine for the prevention of rotavirus, marketed worldwide by GlaxoSmithKline
- Third investment in Rotarix® related roylaties
- Closed in December 2007
- One of the premier UK university institutions for research quality, the College raises more money than any other British university institution and is based in London, England
- Monetized a Royalty for $1.9 million in Temodar®, for the treatment of newly diagnosed brain tumors, marketed by Schering-Plough
- Closed in July 2002
- One of the largest biomedical research institutes in California and one of the top 20 in the United States
- Monetized a Royalty for up to $25 million in Aldurazyme®, for MPS I, co-marketed by Genzyme and Biomarin
- Closed in September 2003
- An independent, not-for-profit research organization founded in 1941 by New York City Mayor Fiorello LaGuardia to study infectious diseases based in Newark, New Jersey
- The inventor and institution monetized a Royalty for $7.6 million in Molecular Beacons technology
- Closed in February 2002
- Independent nonprofit biomedical research institute based in Philadelphia, Pennsylvania
- Monetized a Royalty for $45 million based on RotaTeq®, a vaccine for the prevention of rotavirus, marketed worldwide by Merck
- Closed in November 2005
|
|
Inventors
|
- Three researchers from the institution that ranks third nationally among all pediatric centers in research grants from the National Institutes of Health
- Monetized a Royalty based on Rotarix®, a vaccine for the prevention of rotavirus, marketed worldwide by GlaxoSmithKline
- Closed in November 2005
- An independent, not-for-profit research organization founded in 1941 by New York City Mayor Fiorello LaGuardia to study infectious diseases based in Newark, New Jersey
- The inventor and institution monetized a Royalty for $7.6 million in Molecular Beacons technology
- Closed in February 2002
- Monetized a royalty for up to $7.7 million owed to four University of Chicago Inventors for Relistor®, a novel treatment for opioid induced constipation, marketed worldwide by Wyeth
- Closed in January 2008
|
|